Patents by Inventor John K. Jackson
John K. Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338626Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.Type: ApplicationFiled: July 5, 2023Publication date: October 26, 2023Applicant: COOK MEDICAL TECHNOLOGIES LLCInventor: John K. Jackson
-
Publication number: 20230303817Abstract: The invention provides biocompatible polyvinyl alcohol (PVA) matrices, composed of blends of differently hydrolyzed PVAs. The PVA matrices may be formed into controlled release formulations, for example for topical drug delivery.Type: ApplicationFiled: July 20, 2021Publication date: September 28, 2023Inventors: John K. Jackson, David Plackett, Qianyu Chen, Malihesadat Poormasjedimeibod, Helen M. Burt
-
Publication number: 20230248745Abstract: Pharmaceutical formulations and treatments are provided that make combined use of selected antibiotic cannabinoids with silver-containing medicaments. Therapeutically effective regimens are provided that facilitate positive drug-drug interactions between the cannabinoid and the silver-containing medicament in a subject.Type: ApplicationFiled: July 20, 2021Publication date: August 10, 2023Inventors: John K. Jackson, Charles J. Thompson, Dana M. Lambert, Manisha Dosanjh
-
Patent number: 11707557Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.Type: GrantFiled: February 3, 2022Date of Patent: July 25, 2023Assignee: Cook Medical Technologies LLCInventor: John K. Jackson
-
Publication number: 20230042600Abstract: This invention provides compositions for controlled localized depositing of one or more drugs within a subject. More particularly, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da) and b) a mucoadhesive in polymer. Alternatively, composition may comprise a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw between 200-500 Da) and a second low molecular weight PEG (Mw between 500-2000 Da), b) a water insoluble polymer and c) a mucoadhesive polymer. Furthermore, the composition may further comprise one or more drugs. Also provided are methods of manufacturing and administering the compositions described herein, which are used as biodegradable, injectable mucoadhesive low-viscosity pastes.Type: ApplicationFiled: February 6, 2021Publication date: February 9, 2023Inventors: Veronika Schmitt, John K. Jackson, Martin E. Gleave, Claudia Kesch
-
Publication number: 20220226549Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.Type: ApplicationFiled: February 3, 2022Publication date: July 21, 2022Applicant: COOK MEDICAL TECHNOLOGIES LLCInventor: John K. Jackson
-
Publication number: 20220152207Abstract: This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.Type: ApplicationFiled: October 8, 2021Publication date: May 19, 2022Inventors: John K. Jackson, Martin E. Gleave, Veronika Schmitt, Claudia Kesch
-
Patent number: 11241520Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.Type: GrantFiled: January 22, 2020Date of Patent: February 8, 2022Assignee: COOK MEDICAL TECHNOLOGIES LLCInventor: John K. Jackson
-
Patent number: 11167034Abstract: This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.Type: GrantFiled: June 13, 2018Date of Patent: November 9, 2021Assignee: The University of British ColumbiaInventors: John K. Jackson, Martin E. Gleave, Veronika Schmitt, Claudia Kesch
-
Publication number: 20200155730Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.Type: ApplicationFiled: January 22, 2020Publication date: May 21, 2020Applicant: COOK MEDICAL TECHNOLOGIES LLCInventor: John K. Jackson
-
Publication number: 20200147223Abstract: This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.Type: ApplicationFiled: June 13, 2018Publication date: May 14, 2020Inventors: John K. Jackson, Martin E. Gleave, Veronika Schmitt, Claudia Kesch
-
Patent number: 10525131Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: GrantFiled: July 26, 2018Date of Patent: January 7, 2020Assignees: The University of British Columbia, Centre for Drug Research and DevelopmentInventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20190201528Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: ApplicationFiled: July 26, 2018Publication date: July 4, 2019Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Patent number: 10071160Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: GrantFiled: December 22, 2016Date of Patent: September 11, 2018Assignees: The University of British Columbia, Centre for Drug Research and DevelopmentInventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20170319696Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: ApplicationFiled: December 22, 2016Publication date: November 9, 2017Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Patent number: 9561278Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: GrantFiled: September 28, 2015Date of Patent: February 7, 2017Assignees: The University of British Columbia, Centre for Drug Research and DevelopmentInventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20160114040Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: ApplicationFiled: September 28, 2015Publication date: April 28, 2016Inventors: Helen M. Burt, Donald E. Brooks, Jayachandran N. Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Patent number: 9289584Abstract: Drug delivery devices responsive to at least one external stimulus are described, along with methods for their preparation and use. The devices can be configured to respond to the stimulus, providing “on demand” release of one or more deliverables such as pharmaceutical drugs.Type: GrantFiled: September 13, 2011Date of Patent: March 22, 2016Assignee: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Mu Chiao, John K. Jackson, Fatemeh N. Pirmoradi, Kevin Ou
-
Patent number: 9186410Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: GrantFiled: March 1, 2011Date of Patent: November 17, 2015Assignees: The University of British Columbia, Centre for Drug Research and DevelopmentInventors: Helen Burt, Donald Brooks, Jayachandran Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
-
Publication number: 20130122112Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.Type: ApplicationFiled: March 1, 2011Publication date: May 16, 2013Applicants: Centre for Drug Research and Development, The University of British ColumbiaInventors: Helen M. Burt, Donald Brooks, Jayachandran Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan